EHA 2015 | Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL

Name: Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL
Uploaded: 2015-06-12T00:00:00.000Z
Duration: 1 min 59 s
Description: At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses the outcomes of clinical trials evaluating treatment using chimeric antigen receptor (CAR)-modified T-cells with specificity for CD19 for adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).

Dieter Hoelzer • 12 Jun 2015

EHA 2015

Acute Lymphoblastic Leukemia Leukemia CAR-T

At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses the outcomes of clinical trials evaluating treatment using chimeric antigen receptor (CAR)-modified T-cells with specificity for CD19 for adult and pediatric patients with relapsed or refractory acute lymphoblastic leukemia (ALL).